Page 76 - Read Online

Poznyak et al. Microbiome Res Rep. 2026;5:3 Page 23 of 23

196. Díez-Sainz E, Lorente-Cebrián S, Aranaz P, Riezu-Boj JI, Martínez JA, Milagro FI. Potential mechanisms linking food-derived
microRNAs, gut microbiota and intestinal barrier functions in the context of nutrition and human health. Front Nutr. 2021;8:586564.
DOI PubMed PMC
197. Casado-Bedmar M, Viennois E. MicroRNA and gut microbiota: Tiny but mighty-novel insights into their cross-talk in inflammatory
bowel disease pathogenesis and therapeutics. J Crohns Colitis. 2022;16:992-1005. DOI PubMed PMC
198. Li M, Chen WD, Wang YD. The roles of the gut microbiota-miRNA interaction in the host pathophysiology. Mol Med. 2020;26:101.
DOI PubMed PMC
199. Turner JE, Stockinger B, Helmby H. IL-22 mediates goblet cell hyperplasia and worm expulsion in intestinal helminth infection. PLoS
Pathog. 2013;9:e1003698. DOI PubMed PMC
200. Mizoguchi A. Healing of intestinal inflammation by IL-22. Inflamm Bowel Dis. 2012;18:1777-84. DOI PubMed PMC
201. Han H, Davidson LA, Fan YY, et al. Loss of aryl hydrocarbon receptor suppresses the response of colonic epithelial cells to IL22
signaling by upregulating SOCS3. Am J Physiol Gastrointest Liver Physiol. 2022;322:G93-G106. DOI PubMed PMC
202. Nehmar R, Fauconnier L, Alves-Filho J, et al. Aryl hydrocarbon receptor (Ahr)-dependent Il-22 expression by type 3 innate lymphoid
cells control of acute joint inflammation. J Cell Mol Med. 2021;25:4721-31. DOI PubMed PMC
203. Xiao X, Mao X, Chen D, et al. miRNAs Can affect intestinal epithelial barrier in inflammatory bowel disease. Front Immunol.
2022;13:868229. DOI PubMed PMC
204. Zhao S, Zhu L, Feng W, et al. MicroRNA-602 prevents the development of inflammatory bowel diseases in a microbiota-dependent
manner. Exp Ther Med. 2021;22:1373. DOI PubMed PMC
205. Kyoko OO, Kono H, Ishimaru K, et al. Expressions of tight junction proteins Occludin and Claudin-1 are under the circadian control in
the mouse large intestine: implications in intestinal permeability and susceptibility to colitis. PLoS One. 2014;9:e98016. DOI PubMed
PMC
206. Chen Z, Guan D, Wang Z, et al. Microbiota in cancer: molecular mechanisms and therapeutic interventions. MedComm (2020).
2023;4:e417. DOI PubMed PMC
207. Zhao Y, Zeng Y, Zeng D, et al. Probiotics and microRNA: their roles in the host-microbe interactions. Front Microbiol. 2020;11:604462.
DOI PubMed PMC
208. Ionescu RF, Enache RM, Cretoiu SM, Cretoiu D. the interplay between gut microbiota and miRNAs in cardiovascular diseases. Front
Cardiovasc Med. 2022;9:856901. DOI PubMed PMC
209. Zhao LY, Mei JX, Yu G, et al. Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications.
Signal Transduct Target Ther. 2023;8:201. DOI PubMed PMC
210. Di Vincenzo F, Del Gaudio A, Petito V, Lopetuso LR, Scaldaferri F. Gut microbiota, intestinal permeability, and systemic inflammation:
a narrative review. Intern Emerg Med. 2024;19:275-93. DOI PubMed PMC
211. Shao T, Hsu R, Rafizadeh DL, et al. The gut ecosystem and immune tolerance. J Autoimmun. 2023;141:103114. DOI
212. Dong Y, Yao J, Deng Q, et al. Relationship between gut microbiota and rheumatoid arthritis: a bibliometric analysis. Front Immunol.
2023;14:1131933. DOI PubMed PMC
213. Lv X, Wang X, Wang X, et al. Research progress in arthritis treatment with the active components of Herba siegesbeckiae. Biomed
Pharmacother. 2023;169:115939. DOI
214. Mitra S, Dash R, Nishan AA, Habiba SU, Moon IS. Brain modulation by the gut microbiota: from disease to therapy. J Adv Res.
2023;53:153-73. DOI PubMed PMC
215. Schinzari F, Tesauro M, Cardillo C. Vasodilator dysfunction in human obesity: established and emerging mechanisms. J Cardiovasc
Pharmacol. 2021;78:S40-52. DOI
216. Cunningham M, Azcarate-Peril MA, Barnard A, et al. Shaping the future of probiotics and prebiotics. Trends Microbiol.
2021;29:667-85. DOI

Disclaimer/Publisher’s Note: All statements, opinions, and data contained in this publication are solely those of the individual author(s) and
contributor(s) and do not necessarily reflect those of OAE and/or the editor(s). OAE and/or the editor(s) disclaim any responsibility for harm to
persons or property resulting from the use of any ideas, methods, instructions, or products mentioned in the content.

© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License
(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and
reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and
the source, provide a link to the Creative Commons license, and indicate if changes were made.